Please login to the form below
chronic diseases
This page shows the latest chronic diseases news and features for those working in and with pharma, biotech and healthcare.
Anavex’s CNS drug slows progression of motor and non-motor symptoms in Parkinson’s disease
Independent research also strengthens the case that SIGMAR1 activation has a beneficial effect as a compensatory mechanism to chronic central nervous system (CNS) diseases.
Latest news
-
BMS builds case for cardiovascular drug mavacamten with new analysis
Hypertrophic cardiomyopathy (HCM) is a chronic and progressive disease which causes excessive contraction of the heart muscles and reduces the ability of the left ventricle to fill. ... Mavacamten represents Bristol Myers Squibb’s ongoing dedication to
-
Italy accelerates the path towards digital therapeutics implementation
involvement, such as those aimed at chronic diseases associated with dysfunctional lifestyles and behaviours in which the participatory role of the patient in the care pathway can be particularly relevant, as
-
Relics from the past
In chronic diseases, it is hard to find a therapy for which an enabling app is not being developed.
-
Novo Nordisk launches late-stage study in Alzheimer’s disease
As a company we aspire to address high unmet medical needs within serious chronic diseases, and we are therefore pleased to initiate phase 3 development of semaglutide within Alzheimer’s disease,”
-
Bayer's drop of the future
obviously, one of the world’s most important chronic diseases. ... And it hasn’t stopped there. It’s extended the same idea to hyperlipidaemia and hypertension, the two other big chronic conditions whose populations overlap.
More from news
Approximately 2 fully matching, plus 183 partially matching documents found.
Latest Intelligence
-
Taking centre stage: the role of behaviour change initiatives in the management of long-term conditions
Partly due to interventions around COVID-19, but also due to ever-increasing numbers of people living with chronic conditions. ... The industry has a huge opportunity to combine traditional approaches alongside behaviour change interventions with NHS
-
Successful product commercialisation: what can we learn from the rare disease setting?
This trend is not surprising – in part driven by the pressures facing healthcare budgets through the rising incidence of chronic diseases, as well as the advent of cell and gene therapies ... For many therapies (from chronic diseases to paediatric rare
-
Why digital is the solution to the healthcare crisis
Innovation in the healthcare industry rapidly accelerated as a direct consequence of an ageing population, the rising prevalence of chronic diseases, infrastructure advancements, evolving care models, higher labour costs, staff shortages
-
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Much of this growth is being driven by the urgent need to innovate in chronic diseases such as cancer, diabetes, mental illness, heart disease and respiratory disease. ... Approximately half of all adults worldwide today are living with a chronic
-
The US celebrates five years of biosimilars on the market – a look to the past, present and future
chronic diseases such as rheumatoid arthritis. ... As these medicines become more commonplace, and as the US population continues to age and face rising rates of chronic disease, the associated costs will likely continue to rise.
More from intelligence
Approximately 2 fully matching, plus 59 partially matching documents found.
Latest appointments
-
Kymab appoints its first chief medical officer
She has over 20 years of experience biomedical research and has focused on pathogenic mechanisms, underlying chronic inflammatory diseases and the interface between autoimmunity and cancer.
-
Dr Li Zhou joins TxCell as cell engineering VP
Dr Zhou will lead the team's discovery and engineering activities on Chimeric Antigen Receptor in Treg cells ( CAR-Treg) for immunotherapy of severe chronic autoimmune and inflammatory diseases and organ
-
Sanofi’s US pharma head joins Synta as CEO
She now leads an emerging US-based biopharma focused on the development of small molecule drugs to treat patients with severe medical conditions, including cancer and chronic inflammatory diseases.
-
Medgenics confirms appointment of Dr Marvin Garovoy
The company's Biopump uses a patient's own tissue to continuously produce and deliver their protein therapy and, potentially, has applications in a range of chronic diseases, including diabetes, multiple
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Rethinking our approach to rare disease communications during COVID-19 and beyond
1. For patients and caregivers, especially those affected by chronic multisystem diseases that require care from several specialties, a clear road map for the continuation or realignment of care is often ... Conclusions. It is clear that COVID-19 has
-
Nanobiotechnology, Artificial Intelligence, and Virtual Care
Venk Varadan, Co-founder &CEO at Nanowear, explores the use of cloth-based nanosensor technology, AI, and deep-learning-enabled diagnostics for remote monitoring of congestive heart failure, chronic diseases, and
-
#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Further to this, the tests used to diagnose cardiac diseases function differently between men and women. ... However, once these trials are divided up into specific diseases the underrepresentation becomes clearer, especially in the fields of
-
Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics
therapy for the treatment of airway infections associated with CF, ABPA and other acute and chronic fungal diseases of the respiratory tract.
-
October 2020: diversity and inclusion in clinical trials round-up
In the U.S., these chronic conditions disproportionately affect minority populations, meaning minorities entered the pandemic with health disparities that put them at a disadvantage. ... In the U.S., fewer healthcare providers have training, knowledge,
#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
October 2020: diversity and inclusion in clinical trials round-up
More from PMHub
Approximately 5 fully matching, plus 31 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
-
B2B media account director
-
Competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- First trial of a vaccine against Alzheimer’s launches
- First von Willebrand disease therapy heads new FDA approvals
- Sanofi to buy acne specialist Origimm
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- David Hunt launches independent agency The Considered
PMHub
Viseven
Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...
Latest intelligence
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
